Synergy Pharma (SGYP) Shares Slump Early; Allergan Interest Questioned
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
(Updated - August 24, 2016 9:51 AM EDT)
Synergy Pharma (Nasdaq: SGYP) shares are down early Wednesday. The stock is off around 5 percent with heavy volume at the start. Today's trading action follows a 3 percent drop on Tuesday.
UPDATE - on Mad Money Monday night, Jim Cramer commented:
I don't think that Brent Saunders [CEO of Allergan] is going to buy them ... Look, it's had a good run. It's almost doubled. I would say it's for speculation only. Remember, it can pull back. It's had such a big run.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Gannett (GCI) -Tronc (TRNC) deal still in doubt as banks said to withdraw financing
- CenturyLink (CTL), Level 3 Communications (LVLT) in Advanced Merger Discussions - Bloomberg
- CenturyLink nears deal to merge with Level 3 -sources
Create E-mail Alert Related CategoriesInsiders' Blog, Mergers and Acquisitions, Rumors, Trader Talk
Related EntitiesJim Cramer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!